XR17-33 The relationship between pharmaceutical and medical researchers is under scrutiny because of

XR17-33 The relationship between
pharmaceutical and medical researchers is under scrutiny because of a possible
conflict of interest. The issue that started the controversy was a 1995 case
control study which suggested that the use of calciumchannel blockers to treat
hypertension led to an increased risk of heart disease. This led to an intense
debate in both technical journals and the press. Researchers writing in the New
England Journal of Medicine (‘Conflict of Interest in the Debate over Calcium
Channel Antagonists’, 8 January 1998, p. 101) looked at the 70 reports on the
subject that
»

XR17-33 The relationship between
pharmaceutical and medical researchers is under scrutiny because of a possible
conflict of interest. The issue that started the controversy was a 1995 case
control study which suggested that the use of calciumchannel blockers to treat
hypertension led to an increased risk of heart disease. This led to an intense
debate in both technical journals and the press. Researchers writing in the New
England Journal of Medicine (‘Conflict of Interest in the Debate over Calcium
Channel Antagonists’, 8 January 1998, p. 101) looked at the 70 reports on the
subject that appeared during 1996–1997, classifying them as either favourable,
neutral or critical towards the drugs. The researchers then contacted the
authors of the reports and questioned them about financial ties to
pharmaceutical companies. The results were recorded in the following way:

Column 1: Results of the scientific study:
1 = favourable; 2 = neutral; 3 = critical

Column 2: 1 = financial ties to
pharmaceutical companies; 2 = no ties to pharmaceutical companies Do these data
allow us to infer that research findings on calcium-channel blockers are
affected by whether the research is funded by a pharmaceutical company?

»